Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

Shaji K. Kumar, Norbert Grzasko, Sosana Delimpasi, Wieslaw W. Jedrzejczak, Sebastian Grosicki, Marie Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m 2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28-day cycles. The primary endpoint was overall response rate (ORR). Seventy-eight patients were enrolled (median age 63·5 years). At data cut-off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow-up of 15·2 months, median progression-free survival (PFS) was 14·2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18·7 months vs. 12·0 months; hazard ratio 0·62, P = 0·14). ICd was well tolerated. The most common treatment-emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070).

Original languageEnglish (US)
Pages (from-to)536-546
Number of pages11
JournalBritish journal of haematology
Volume184
Issue number4
DOIs
StatePublished - Feb 1 2019

Keywords

  • ixazomib
  • proteasome inhibitor
  • relapsed myeloma
  • response
  • survival

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Kumar, S. K., Grzasko, N., Delimpasi, S., Jedrzejczak, W. W., Grosicki, S., Kyrtsonis, M. C., Spencer, A., Gupta, N., Teng, Z., Byrne, C., Labotka, R., & Dimopoulos, M. A. (2019). Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. British journal of haematology, 184(4), 536-546. https://doi.org/10.1111/bjh.15679